Anavex life sciences to present at the dawson james securities 6th annual conference

New york, oct. 15, 2021 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including alzheimer's disease, parkinson's disease, rett syndrome and other central nervous system (cns) disorders, today announced that christopher u. missling, phd, president and chief executive officer of anavex, will present at the dawson james securities 6th annual conference on thursday, october 21, 2021 at 1:30 pm (et).
AVXL Ratings Summary
AVXL Quant Ranking